Additional Resources

New data regarding the prevention, diagnosis, and management of COVID-19 are emerging daily. Please see the list of COVID-19 resources for healthcare professionals provided below for additional up-to-date and comprehensive information.

Resources CDC, HHS, NIH, and WHO

US Department of Health and Human Services (HHS). Find ways to prevent, treat or help fight COVID-19. https://combatcovid.hhs.gov/

National Institutes of Health (NIH). COVID-19 Treatment Guidelines. https://covid19treatmentguidelines.nih.gov/introduction/

Centers for Disease Control and Prevention (CDC). Evaluating and Testing Persons for Coronavirus Disease 2019 (COVID-19). https://www.cdc.gov/coronavirus/2019-nCoV/hcp/clinical-criteria.html

CDC. Interim Clinical Guidance for Management of Patients with Confirmed Coronavirus Disease (COVID-19). https://www.cdc.gov/coronavirus/2019-ncov/hcp/clinical-guidance-management-patients.html

NIH. COVID-19 Treatment Guidelines. https://covid19treatmentguidelines.nih.gov/introduction/

CDC. Information for Healthcare Professionals about Coronavirus (COVID-19). https://www.cdc.gov/coronavirus/2019-nCoV/hcp/index.html

World Health Organization (WHO). Country & Technical Guidance – Coronavirus disease (COVID-19). https://www.who.int/emergencies/diseases/novel-coronavirus-2019/technical-guidance

Additional Guidance on the Management of Patients with COVID-19.

Society of Critical Care Medicine. Surviving Sepsis Campaign: COVID-19 Guidelines. https://www.sccm.org/SurvivingSepsisCampaign/Guidelines/COVID-19

Infectious Disease Society of America (IDSA). COVID-19 Resource Center. https://www.idsociety.org/public-health/COVID-19-Resource-Center/

IDSA. Infectious Diseases Society of America Guidelines on Infection Prevention in Patients with Suspected or Known COVID-19. https://www.idsociety.org/practice-guideline/covid-19-guideline-infection-prevention/

Recommendations on the Management of Special Populations During the COVID-19 Pandemic.

Al-Shamsi HO, Alhazzani W, Alhuraiji A, et al. A practical approach to the management of cancer patients during the novel coronavirus disease 2019 (COVID-19) pandemic: an international collaborative group. Oncologist. 2020. https://doi.org/10.1634/theoncologist.2020-0213

American College of Surgeons (ACS). Recommendations for prioritization, treatment and triage of breast cancer patients during the COVID-19 pandemic. Available at https://www.facs.org/quality-programs/cancer/executive-summary

American Society of Clinical Oncology (ASCO). COVID-19 Patient Care Information. https://www.asco.org/asco-coronavirus-information/care-individuals-cancer-during-covid-19

Centers for Disease Control and Prevention (CDC). Considerations for Inpatient Obstetric Healthcare Settings. https://www.cdc.gov/coronavirus/2019-ncov/hcp/inpatient-obstetric-healthcare-guidance.html

American College of Obstetricians and Gynecologists (ACOG). Novel Coronavirus 2019 (COVID-19). https://www.acog.org/clinical/clinical-guidance/practice-advisory/articles/2020/03/novel-coronavirus-2019

Supporting Patient Journeys Through Resources and Tools to Promote Positive Patient Outcomes in Care

National Infusion Center Association. COVID-19 Antibody Therapies Resource Center. https://infusioncenter.org/infusion_resources/covid-19-antibody-treatment-resource-center/

CombatCOVID.hhs.gov. Monoclonal Antibodies for High-Risk COVID-19 Positive Patients. https://combatcovid.hhs.gov/i-have-covid-19-now/monoclonal-antibodies-high-risk-covid-19-positive-patients?gclid=EAIaIQobChMI4r-5loX27gIVCaiGCh3AQgwgEAAYASAAEgI76fD_BwE

Joost Wiersinga W, et al. Pathophysiology, transmission, diagnosis, and treatment of coronavirus disease 2019 (COVID-19): A review. JAMA. 2020;10.1001/jama.2020.12839. https://pubmed.ncbi.nlm.nih.gov/32648899/

Guan WJ, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. 2020;382:1708-1720. https://pubmed.ncbi.nlm.nih.gov/32109013/

Rothan HA, et al. The epidemiology and pathogenesis of coronavirus disease (COVID-19) outbreak. J Autoimmun. 2020;109:102433. https://pubmed.ncbi.nlm.nih.gov/32113704/

Lechien JR, et al. Clinical and epidemiological characteristics of 1420 European patients with mild-to-moderate coronavirus disease 2019. [published online ahead of print, 2020 Apr 30]. J Intern Med. 2020; 10.1111/joim.13089. https://pubmed.ncbi.nlm.nih.gov/32352202/

Wang W, et al. Updated understanding of the outbreak of 2019 novel coronavirus (2019-nCoV) in Wuhan, China. J Med Virol. 2020;92:441-447. https://pubmed.ncbi.nlm.nih.gov/31994742/

Wu Z, et al. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: Summary of a report of 72 314 cases from the Chinese Center for Disease Control and Prevention. JAMA. 2020;323:1239-1242. https://jamanetwork.com/journals/jama/fullarticle/2762130

Richardson S, et al. Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York City area. JAMA. 2020 May 26;323:2052–2059. https://pubmed.ncbi.nlm.nih.gov/32320003/

Docherty AB, et al. Features of 20,133 UK patients in hospital with COVID-19 using the ISARIC WHO Clinical Characterisation Protocol: Prospective observational cohort study. BMJ. 2020;369:m1985. https://www.bmj.com/content/369/bmj.m1985

Yuan X, et al. Changes of hematological and immunological parameters in COVID-19 patients. [published online ahead of print, 2020 Jul 12]. Int J Hematol. 2020;1-7. https://pubmed.ncbi.nlm.nih.gov/32656638/

Bhimraj A, et al. Infectious Diseases Society of America Guidelines on the Treatment and Management of Patients with COVID-19. IDSA Guidelines. V2.1.0. https://www.idsociety.org/practice-guideline/covid-19-guideline-treatment-and-management/

Alhazzani W, et al. Surviving Sepsis Campaign: Guidelines on the management of critically ill adults with coronavirus disease 2019 (COVID-19). Intensive Care Med. 2020;46:854-887. https://pubmed.ncbi.nlm.nih.gov/32222812/

World Health Organization (WHO). Clinical management of COVID-19. Interim Guidance. 2020 May 27. https://www.who.int/publications/i/item/clinical-management-of-covid-19

National Institutes of Health (NIH). COVID-19 Treatment Guidelines. https://www.covid19treatmentguidelines.nih.gov/

Beigel JH, et al. Remdesivir for the treatment of COVID-19 – Final Report. N Engl J Med. 2020;383:1813-1826. https://www.nejm.org/doi/full/10.1056/NEJMoa2007764

Spinner CD, et al. Effect of remdesivir vs standard care on clinical status at 11 days in patients with moderate COVID-19: a randomized clinical trial. JAMA. 2020;324:1048-1057. https://jamanetwork.com/journals/jama/fullarticle/2769871

Horby P, et al. Dexamethasone in hospitalized patients with COVID-19 – preliminary report. N Engl J Med. 2020;Epub ahead of print. https://pubmed.ncbi.nlm.nih.gov/32678530/

Siddiqi HK, et al. COVID-19 illness in native and immunosuppressed states: A clinical-therapeutic staging proposal. J Heart Lung Transplant. 2020;39:405-407. https://www.jhltonline.org/article/S1053-2498(20)31473-X/fulltext

Li L, et al. Effect of convalescent plasma therapy on time to clinical improvement in patients with severe and life-threatening COVID-19: A randomized clinical trial. [published online ahead of print, 2020 Jun 3].JAMA. 2020;e2010044. https://pubmed.ncbi.nlm.nih.gov/32492084/

Kalil AC, et al. Baricitinib plus remdesivir for hospitalized adults with COVID-19. N Engl J Med. 2020;Epub ahead of print. https://www.nejm.org/doi/full/10.1056/NEJMoa2031994

Baum A, et al. Antibody cocktail to SARS-CoV-2 spike protein prevents rapid mutational escape seen with individual antibodies. Science. 2020;369:1014-1018. https://pubmed.ncbi.nlm.nih.gov/32540904/

Gandhi RT, et al. Mild or moderate COVID-19. N Engl J Med. 2020;383:1757-1766. https://pubmed.ncbi.nlm.nih.gov/32329974/

Docherty AB, et al. Features of 20 133 UK patients in hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol: prospective observational cohort study. BMJ. 2020;369:m1985. https://pubmed.ncbi.nlm.nih.gov/32444460/

Simonovich VA, et al. A Randomized Trial of Convalescent Plasma in Covid-19 Severe Pneumonia. N Engl J Med. 2020;Epub ahead of print. https://pubmed.ncbi.nlm.nih.gov/33232588/

Fact Sheet for Health Care Providers Emergency Use Authorization (EUA) of Baricitinib. https://www.fda.gov/media/143823/download

Fact Sheet for Health Care Providers Emergency Use Authorization (EUA) of Bamlanivimab. http://pi.lilly.com/eua/bamlanivimab-eua-factsheet-hcp.pdf

Fact Sheet for Health Providers Emergency Use Authorization (EUA) of Bamlanivimab and Etesevimab. https://www.fda.gov/media/145802/download

Fact Sheet for Health Care Providers Emergency Use Authorization (EUA) of Casirivimab and Imdevimab. https://www.fda.gov/media/143892/download

Fact Sheet for Health Care Providers Emergency Use Authorization (EUA) of COVID-19 Convalescent Plasma for Treatment of Hospitalized Patients with COVID-19. https://www.fda.gov/media/141478/download

Weinreich DM, et al. REGN-COV2, a neutralizing antibody cocktail, in outpatients with COVID-29. N Engl J Med. 2020;Epub ahead of print. https://www.nejm.org/doi/pdf/10.1056/NEJMoa2035002

Gottlieb RL, et al. Effect of bamlanivimab as monotherapy or in combination with etesevimab on viral load in patients with mild to moderate COVID-19: a randomized clinical trial. JAMA. 2021;325:632-644. https://jamanetwork.com/journals/jama/fullarticle/2775647

Chen P, et al. SARS-CoV-2 Neutralizing Antibody LY-CoV555 in Outpatients with Covid-19. N Engl J Med. 2020;Epub ahead of print. https://www.nejm.org/doi/full/10.1056/NEJMoa2029849

ACTIV-3/TICO LY-CoV555 Study Group. A neutralizing monoclonal antibody for hospitalized patients with COVID-19. N Engl J Med. 2020;Epub ahead of print. https://www.nejm.org/doi/full/10.1056/NEJMoa2033130

Hansen J, et al. Studies in humanized mice and convalescent humans yield a SARS-CoV-2 antibody cocktail. Science. 2020;369:1010-1014. https://science.sciencemag.org/content/369/6506/1010

Callaway E. The coronavirus is mutating – does it matter? Nature. 2020;585:174-177. https://www.nature.com/articles/d41586-020-02544-6

Menu

Updates in the Treatment and Prevention of COVID-19​

Casirivimab and Imdevimab Approved in Japan for the Treatment of Mild-to-Moderate COVID-19

Japan’s Ministry of Health, Labour and Welfare (MHLW) has fully approved the combination of casirivimab and imdevimab to treat patients with mild-to-moderate COVID-19. This marks the first time a monoclonal-antibody cocktail has received full approval to treat COVID-19. This combination therapy is currently authorized for emergency use in more than 20 countries, including the United States, European Union, India, Switzerland, and Canada. The monoclonal antibody cocktail was approved in Japan after results from a phase 3 trial showed a 70% reduction in the risk of hospitalization or death in high-risk non-hospitalized patients who received casirivimab and imdevimab. The MHLW also reviewed results from a phase 1 trial that analyzed the safety, tolerability, and pharmacokinetics of the combination therapy in Japanese subjects. Multiple analyses have shown that casirivimab and imdevimab retain potency against circulating variants of concern, including Delta (B.1.162.2, first seen in India), Gamma (P.1, first seen in Brazil), and Beta (B.1.351, first seen in South Africa).

Reference

https://newsroom.regeneron.com/news-releases/news-release-details/japan-becomes-first-country-approve-regeneron-antibody-cocktail